Market Overview

UPDATE: ISI Group Initiates Becton, Dickinson and Co. at Buy on Multiple Positive Factors

Share:
Related BDX
Benzinga's Top Upgrades
UBS Upgrades Becton Dickinson To Buy
The Vetr community has downgraded $BDX to 3-Stars (Vetr)

In a report published Tuesday, ISI Group analyst Vijay Kumar initiated coverage on Becton, Dickinson and Co. (NYSE: BDX) with a Buy rating and $106.50 price target.

In the report, ISI Group noted, “We view Becton, Dickinson and Co (BDX) as a premier provider of medical devices, diagnostic instruments, and reagents to hospitals as well as pharma, academic, and clinical labs. We contend that the company's attractively diversified portfolio (Medical ~50% of revs, Diagnostics ~35% of revs and Biosciences ~15% of revs), should allow for mid single digit top-line growth over the medium-term. This will be driven mainly by new product momentum, increased leverage to the emerging markets, and continued strength in safety engineered products. With respect to new product momentum, we see several offerings that have been underappreciated by the Street including: BD Max (MDx), BD Rx (prefilled generics), Kiestra microbiology automation (MDx), Carmel closed drug transfer systems, Accuri flocytometry, and Sirigen (reagents). When combined with advancements in pen needles, we expect innovation to contribute ~250 bps to organic growth going forward. Lastly, we believe that emerging markets (~25% of revs) will continue to grow low double digits (with China up strong double digits), while safety engineered products (prevention of needle sticks) should expand in the high single digit range.”

Becton, Dickinson and Co. closed on Monday at $97.72.

Latest Ratings for BDX

DateFirmActionFromTo
Jul 2015BarclaysReinstatesEqual-weight
Jun 2015UBSUpgradesBuy
Mar 2015Goldman SachsReinstatesNeutral

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: ISI Group Vijay KumarAnalyst Color Initiation Analyst Ratings

 

Related Articles (BDX)

Get Benzinga's Newsletters